SCHEMBL13055751

SCHEMBL13055751

CC(=O)Oc1ccc(C(=O)Nc2nc(S(=O)(=O)C(F)(F)F)cs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.53
HSD17B10 Q99714 1/20 0.53
MAPT P10636 4/20 0.46
NPC1 O15118 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
LMNA P02545 4/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
GAA P10253 1/20 0.45
ADORA3 P0DMS8 2/20 0.44
MAPK1 P28482 2/20 0.43
HSP90AA1 P07900 1/20 0.43
F2 P00734 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 2/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL705314 0.86 RAB9A (0.57) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL13055749 0.81 RAB9A (0.57) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL13055708 0.78 RAB9A (0.53) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL13055821 0.78 KMT2A (0.45) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL704433 0.75 RAB9A (0.58) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL2696751 0.74 RAB9A (0.56) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL706481 0.73 GCK (0.59) RAB9AMAPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL13055742 0.73 NPC1 (0.61) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL10114656 0.72 RAB9A (0.44) RAB9AHSD17B10MAPTNPC1SMN1; SMN2
SCHEMBL13055886 0.72 SMN1; SMN2 (0.40) RAB9AHSD17B10MAPTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47786-E1 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES L.C. (US) 2019-12-31 US disclosed
US-RE46724-E1 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES, L.C. (US) 2018-02-20 US disclosed
US-RE46724-E1 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES, L.C. (US) 2018-02-20 US disclosed
US-9126992-B2 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES, L.C. (US) 2015-09-08 US disclosed
US-20140341850-A1 HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS ROMARK LABORATORIES, L.C. (US) 2014-11-20 US disclosed
US-20140341850-A1 HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS ROMARK LABORATORIES, L.C. (US) 2014-11-20 US disclosed
US-8846727-B2 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES, L.C. (US) 2014-09-30 US disclosed
US-8846727-B2 Haloalkyl heteroaryl benzamide compounds ROMARK LABORATORIES, L.C. (US) 2014-09-30 US disclosed
US-20100292274-A1 HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS ROMARK LABORATORIES L.C. 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292274-A1 HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS HDHD5, HAVCR2, AADAC RAB9A 1886/4885HSD17B10 238/4885MAPT 4286/4885
US-20140341850-A1 HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS HDHD5, HAVCR2, AADAC RAB9A 1886/4885HSD17B10 238/4885MAPT 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.